ALFA Finder| Revenue growth | 19% YoY for FY26; 18% YoY for Q4 FY26. |
|---|---|
| Margins | Adjusted EBITDA margin improved from 12.7% to 13.4% in FY26. |
| Demand visibility | Strong growth in Chronic (53%) and Complex Generic (74%) portfolios. |
| Management confidence | High; citing 13 consecutive quarters of record revenue. |
Growth
Revenue grew 19% YoY to ₹904 Cr; Adjusted PAT increased 31% YoY to ₹83 Cr in FY26.
Outlook
Plant-6 OSD facility mechanical completion achieved; commercialization targeted for H1 FY27. Proposed dividend of ₹13 Cr.
Risks
Moderate industry volume growth (2.7% in IPM); lead times associated with export market regulatory approvals.
Earnings Call filed with NSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹998.85
- Market cap
- ₹2,096 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 31.4×Sector 43.8×
- Promoter holding
- 63.31%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Management Change
Windlass Biotech reports Mr. Ashok Kumar Windlass ceased as Executive Director, resigning for succession planning, effective 5 November 2026. He moves to Founder President, and Hitesh Windlass becomes Managing Director.
Windlas Biotech Results Update
Windlas Biotech reported H1 FY27 revenue of Rs 512 crore, up 18% YoY. Adjusted PAT rose 33% to Rs 50 crore for the half year.
Windlas Biotech Investor Presentation: Key Takeaways
H1FY27 revenue Rs 512 Cr (+18%), adj. PAT Rs 50 Cr (+33%, 9.7% margin); reported PAT flat at Rs 36 Cr on ESOP charges. CDMO-led growth; Plant-6 commercialised.
Windlas Biotech Q2 FY27 Results: Net Profit ₹18.1 Cr, Up 1.7% YoY
Windlas Biotech Ltd reported revenue from operations of ₹263.9 Cr (+18.7% YoY) and net profit of ₹18.1 Cr (+1.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.1 Cr · +1.7% YoY
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Windlas Biotech Board Meeting Date
Windlas Biotech intimated that its Board meeting is scheduled for 5 November 2026 to consider unaudited standalone results for Q1 FY27. No monetary figure is disclosed in this advance notice.